These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22396600)

  • 1. Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.
    Sagar M; Akiyama H; Etemad B; Ramirez N; Freitas I; Gummuluru S
    J Infect Dis; 2012 Apr; 205(8):1248-57. PubMed ID: 22396600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody.
    van Montfort T; Thomas AA; Krawczyk PM; Berkhout B; Sanders RW; Paxton WA
    J Immunol; 2015 Oct; 195(8):3759-68. PubMed ID: 26355155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes.
    van Montfort T; Nabatov AA; Geijtenbeek TB; Pollakis G; Paxton WA
    J Immunol; 2007 Mar; 178(5):3177-85. PubMed ID: 17312166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
    Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
    Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
    Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
    Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
    Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.
    Barbian HJ; Decker JM; Bibollet-Ruche F; Galimidi RP; West AP; Learn GH; Parrish NF; Iyer SS; Li Y; Pace CS; Song R; Huang Y; Denny TN; Mouquet H; Martin L; Acharya P; Zhang B; Kwong PD; Mascola JR; Verrips CT; Strokappe NM; Rutten L; McCoy LE; Weiss RA; Brown CS; Jackson R; Silvestri G; Connors M; Burton DR; Shaw GM; Nussenzweig MC; Bjorkman PJ; Ho DD; Farzan M; Hahn BH
    mBio; 2015 Apr; 6(2):. PubMed ID: 25900654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.
    Bouvin-Pley M; Morgand M; Meyer L; Goujard C; Moreau A; Mouquet H; Nussenzweig M; Pace C; Ho D; Bjorkman PJ; Baty D; Chames P; Pancera M; Kwong PD; Poignard P; Barin F; Braibant M
    J Virol; 2014 Dec; 88(23):13910-7. PubMed ID: 25231299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
    Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
    PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.
    Kesavardhana S; Das R; Citron M; Datta R; Ecto L; Srilatha NS; DiStefano D; Swoyer R; Joyce JG; Dutta S; LaBranche CC; Montefiori DC; Flynn JA; Varadarajan R
    J Biol Chem; 2017 Jan; 292(1):278-291. PubMed ID: 27879316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
    Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
    PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.